Currently, the number of people with non-alcoholic fatty liver disease is increasing rapidly. If non-alcoholic fatty liver disease is not detected and treated promptly, it will cause serious consequences. There are many causes of nonalcoholic fatty liver.

G protein-coupled receptors and their signaling pathways are promising targets for the treatment of NAFLD. Accordingly, studies of the gut-hepatic axis are rapidly contributing to the collection of evidence that dysbiosis of the gut microbiota contributes to NAFLD progression through multiple mechanisms.

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of chronic liver disease, ranging from steatosis at one end to fibrosis and cirrhosis at the other. NASH and NASH are the hepatic manifestations of the metabolic syndrome (MetS), which drives a multitude of comorbidities, such as insulin resistance, cardiovascular disease (CVD), chronic kidney disease (CKD), obstructive sleep apnea (OSA), as well as an increased risk of malignancy.

Physicians recommend that patients with diabetes and nonalcoholic fatty liver disease should be routinely monitored for underlying renal dysfunction, rather than just patients with diabetes. Monitoring thyrotropin and thyroid hormone levels may be clinically useful when assessing the risk of developing chronic kidney disease in patients with nonalcoholic fatty liver disease; however, future studies are needed to specifically address the risk of chronic kidney disease in patients with nonalcoholic fatty liver disease and hypothyroidism.

With the increasing prevalence of obesity and diabetes in the United States and worldwide, the overall prevalence of nonalcoholic fatty liver disease (NAFLD) is expected to increase. Risk factors for NAFLD are also associated with the development of chronic kidney disease (CKD). We review the epidemiology, risk factors, genetics, the impact of gut dysbiosis, and the specific pathogenic mechanisms linking NAFLD to chronic kidney disease.

Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major cause of chronic liver disease in the industrialized world. The prevalence of NAFLD is not only increased in patients with type 2 diabetes, metabolic syndrome, and obesity, but is also associated with more severe forms of the disease, with a significant proportion of subjects developing NAFLD despite having a relatively normal body mass index (BMI), a condition known as non-obese or lean NAFLD.

The incidence of non-alcoholic fatty liver disease (NAFLD) is significantly increased in people with a relatively normal body mass index (BMI), a condition known as non-obese non-alcoholic fatty liver disease or lean non-alcoholic fatty liver disease. The following article is a review of studies on the prognosis of patients with non-obese non-alcoholic fatty liver disease.